Burkholderia cepacia complex (BCC)
isolates are causes of healthcare-associated infection, especially in relation
to contamination of aqueous inhalers and some intravenously administered
products. The bacterial species can cause opportunistic infections in
vulnerable individuals, especially those with cystic fibrosis (CF).
The
organisms can cause pneumonia in immunocompromised individuals (especially when
introduced into the air passages of a susceptible population). In the past
decade, organisms that fall within the BCC grouping have been identified as
potentially ‘objectionable’ within the pharmaceutical manufacturing
environment; especially given the connection between such organisms and
non-sterile products and the target patient population that includes the young,
elderly and immunocompromised.
This
article reviews the origins of Burkholderia
cepacia in pharmaceutical facilities and the particular risks that it poses
to patient populations. The article also considers the optimal test methods to
use to screen for the organism group.
The
reference is:
Foe a copy please contact Tim Sandle
Posted by Dr. Tim Sandle,
Pharmaceutical Microbiology
No comments:
Post a comment
Pharmaceutical Microbiology Resources